Please login to the form below

Not currently logged in
Email:
Password:

TH-302

This page shows the latest TH-302 news and features for those working in and with pharma, biotech and healthcare.

Merck abandons evofosfamide as two trials fail

Merck abandons evofosfamide as two trials fail

The decision was taken after evofosfamide (TH-302) failed to show any improvement in overall survival in the trials, which involved patients with metastatic pancreatic cancer and soft tissue sarcoma who

Latest news

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics